Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

ZITUVIO 25 MG TABLET

Sitagliptin
$10.0447per EA

Strength

25 mg/1

Manufacturer

Zydus Pharmaceuticals (USA) Inc.

NDC

70710124003

Classification

Brand

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

SITAGLIPTIN

Approval Type

New Drug (NDA)

FDA Application

NDA211566

On Market Since

11/30/2023

Pharmacological Classes

Dipeptidyl Peptidase 4 Inhibitor
Dipeptidyl Peptidase 4 Inhibitors

Price History

1W

0.0%

1M

-0.1%

3M

-0.0%

6M

+0.0%

1Y

N/A

3Y

N/A

5Y

N/A

All

-0.7%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

ZITUVIMET XR 50-1,000 MG TABLET
Brand
70710180506•Zydus Pharmaceuticals (USA) Inc.
$5.0263
per EA
ZITUVIMET 50-1,000 MG TABLET
Brand
70710178706•Zydus Pharmaceuticals (USA) Inc.
$5.0308
per EA
ZITUVIMET 50-500 MG TABLET
Brand
70710178606•Zydus Pharmaceuticals (USA) Inc.
$5.0779
per EA
JANUMET XR 50-1,000 MG TABLET
Brand
00006008061•Merck Sharp & Dohme LLC
$5.2761
per EA
JANUMET XR 50-1,000 MG TABLET
Brand
00006008062•Merck Sharp & Dohme LLC
$5.2761
per EA
JANUMET XR 50-1,000 MG TABLET
Brand
00006008082•Merck Sharp & Dohme LLC
$5.2761
per EA
JANUMET 50-1,000 MG TABLET
Brand
00006057761•Merck Sharp & Dohme LLC
$5.2792
per EA
JANUMET 50-1,000 MG TABLET
Brand
00006057762•Merck Sharp & Dohme LLC
$5.2792
per EA
JANUMET 50-1,000 MG TABLET
Brand
00006057782•Merck Sharp & Dohme LLC
$5.2792
per EA
JANUMET XR 50-500 MG TABLET
Brand
00006007861•Merck Sharp & Dohme LLC
$5.2815
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy